Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study)

BACKGROUND: In the AVAGAST study, fluoropyrimidine and cisplatin plus bevacizumab did not significantly improve overall survival (OS) versus fluoropyrimidine and cisplatin plus placebo in patients with advanced gastric cancer. Geographic differences in efficacy were observed in AVAGAST, but the stud...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Gastric Cancer
Asıl Yazarlar: Shen, Lin, Li, Jin, Xu, Jianming, Pan, Hongming, Dai, Guanghai, Qin, Shukui, Wang, Liwei, Wang, Jinwan, Yang, Zhenzhou, Shu, Yongqian, Xu, Ruihua, Chen, Lei, Liu, Yunpeng, Yu, Shiying, Bu, Lilian, Piao, Yongzhe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Japan 2014
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4544634/
https://ncbi.nlm.nih.gov/pubmed/24557418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-014-0351-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller